Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 8

Global Laparoscopic Device Market Poised for Growth Amid Technological Advancements and Increasing Procedural Volume

The global laparoscopic device market is set for sustained growth driven by increasing procedural volumes, technological advancements, and a shift towards minimally invasive surgical techniques.

Key components of this market include laparoscopes, trocars, hand instruments, insufflators, and suction-irrigation pumps. These devices enable visualization and access for various abdominal and pelvic surgeries, contributing to the efficiency of laparoscopic procedures worldwide.

The market’s growth is primarily fueled by the demand for disposable laparoscopic instruments, sustained by the high procedural volume. Closure devices represent the largest segment, accounting for 40% of the global market value, underscoring the importance of these devices in minimally invasive surgeries.

Rising Demand for Laparoscopic Treatments Driven by Prevalence of Cancer and Gastrointestinal Disorders

Laparoscopic devices are integral in treating a variety of conditions, including gynecologic cancers, colorectal issues, and gastrointestinal disorders, with prevalence rates varying significantly across regions. In the U.S., gynecologic cancers are a major concern, with approximately 94,000 diagnoses and nearly 28,000 deaths annually. Uterine cancer remains the fourth most common cancer among women in the U.K., while ovarian cancer presents a substantial burden, with an estimated 19,880 new cases and 12,810 deaths in the U.S. in 2022 alone. Colorectal cancer is another major area of concern, ranking as the third most commonly diagnosed cancer worldwide, with higher incidence rates observed in Western Europe and East Asia. Hernia repairs, particularly for inguinal hernias, are common procedures in the U.S., where around one million abdominal wall hernia surgeries are performed each year. Additionally, diverticulitis and Crohn’s disease are prevalent, especially in Western nations, where advanced diagnostic techniques and prompt treatment contribute to higher reported incidence rates. The need for laparoscopic interventions continues to grow globally as minimally invasive approaches become the standard for managing these widespread conditions.

Regional Trends

North America, Asia-Pacific, and Western Europe collectively dominate the global laparoscopic device market due to higher unit sales, device costs, and favorable demographic trends. These regions are projected to maintain their leadership positions throughout the forecast period.

The global market is expected to experience a steady single-digit growth rate, driven by demographic shifts and the ongoing adoption of minimally invasive techniques. While laparoscopy is evolving toward robotic-assisted surgery, the development and adoption of new technologies may be tempered by current hospital priorities, such as infection prevention and managing elective surgery backlogs from the pandemic.

The laparoscopic device market is expanding beyond North America and Europe, with significant growth in Latin America and Asia-Pacific. In Latin America, countries like Brazil, Mexico, and Argentina are seeing increased laparoscopic surgeries due to rising disease burdens and healthcare improvements. Meanwhile, in Asia-Pacific, including China, India, and Japan, demand is driven by an aging population, lifestyle changes, and investments in healthcare. As laparoscopy becomes the standard for many surgeries in these regions, the market is set for strong growth, creating opportunities for manufacturers and fueling global expansion.

Increasing Adoption of Laparoscopy in Diverse Procedures

Laparoscopic techniques continue to replace traditional open surgery, particularly in Europe, where the number of laparoscopic procedures is steadily increasing. Laparoscopy’s advantages, including reduced recovery time and shorter hospital stays, are driving the adoption of these techniques, even enabling many procedures to be performed in outpatient settings. However, outpatient care remains less developed in Europe compared to the U.S.

The U.S. market has also seen consistent growth in laparoscopic procedures, particularly in hernia repair, nephrectomy, colectomy, and sleeve gastrectomy. Cholecystectomy was the most common laparoscopic procedure performed in 2022. The ongoing introduction of innovative devices is expected to further enhance the efficiency and clinical outcomes of these procedures. However, the rise of robotic-assisted surgery poses a limiting factor on the growth of standard laparoscopic device segments.

Competing Technologies in Minimally Invasive Surgery

In Europe, the ultrasonic laparoscopic device market has grown rapidly, challenging the dominance of direct energy devices. The rise in minimally invasive surgery has fueled demand for ultrasonic devices, which offer precise tissue dissection, minimal damage to surrounding tissues, and shorter operating times. Technological advancements like tissue recognition and vessel sealing have improved safety and efficiency, while reduced smoke and odor compared to electrosurgical tools enhance the surgical environment.

In the U.S., the laparoscopic direct energy device market remains strong, driven by innovation and increased use of minimally invasive techniques. Despite ongoing development in precision and specialized devices, challenges such as high costs and training requirements persist, along with concerns over risks like thermal injury. Both markets show growth, with Europe’s ultrasonic devices gaining traction as a competitive alternative, while direct energy devices maintain a dominant position in the U.S.

Market Leaders: Medtronic, Ethicon, and Karl Storz

Medtronic emerged as the leading competitor in the global laparoscopic device market in 2023, driven by its LigaSure™ vessel sealing system and Endo GIA™ stapling products. The company’s innovation, such as Tri-Staple™ technology and SILS™ single-port instruments, bolstered its strong market presence.

Ethicon followed closely behind, with significant market share in closure devices and ultrasonic energy products, notably the HARMONIC® line. Its diverse trocar portfolio and leadership in ultrasonic device technology position it as a major player in the market.

Karl Storz ranked third, capitalizing on its expertise in reusable hand instruments and laparoscopes. The company’s dominance in the hand instrument market, coupled with its well-established HOPKINS® rod lens laparoscopes and Endoflator® insufflators, contributed to its success.

Other competitors within  this market include Olympus, Stryker, Applied Medical, CONMED, Richard Wolf, Becton Dickinson, B. Braun, ERBE, Allurion, LiNA Medical, Microline Surgical, BOWA Medical, and more.

Outlook

The global laparoscopic device market is expected to benefit from the ongoing transition to minimally invasive surgical techniques and the introduction of innovative products that enhance procedural efficiency. While robotic-assisted surgery may limit growth in some segments, the overall demand for laparoscopic devices will remain strong due to increasing procedural volumes and evolving surgical standards.

 

Nordic and BeeKeeperAI Partner | To Accelerate AI-driven Clinical Decision Support at the Point of Care

Nordic, a global health and technology consulting company, and BeeKeeperAI®, Inc. a pioneer in privacy-enhancing, multi-party collaboration software for real-world AI development and deployment, announced today a strategic partnership to bring to market a new real-world, end-to-end RightAI™ solution that is aimed at connecting biopharmaceutical and medical technology companies, healthcare delivery organizations, and physicians in the development, validation, and deployment of AI and machine learning-based CDSS tools that support clinical workflows within electronic health record (EHR) systems.

The partnership intends for RightAI to assist physicians with optimizing patient outcomes through the use of native CDSS tools within the EHR and support efforts to identify patients who are optimal candidates for clinical trials.

Precise decision-making at the point of care can be difficult given a variety of factors, such as a patient’s unique clinical characteristics, chronic conditions, and the complexities of biological and disease factors. The development of a new standard of care resulting from the collaboration between biopharmaceutical and medical technology companies and healthcare systems can enable new personalized care programs, provide novel therapies, and meet patients’ goals for better health. RightAI seeks to offer solutions that enable clinicians to identify these optimal treatment plans for the right patient at the right time. Leveraging the power of data at the point of care from this collaboration can transform care delivery.

“By embracing AI in healthcare, we are transforming how care is delivered and setting a new standard for patient-centered, personalized, and efficient care,” said Nordic Chief Medical Officer Craig Joseph, MD. “Our partnership with BeeKeeperAI and the integration of RightAI into the EHR allows us to introduce AI models that create real-world impact and drive better patient outcomes.”

Along with the potential both to unlock data insights and enable more precise therapeutic decisions by clinicians, RightAI also intends to accelerate time-to-market for AI developers building CDSSs and other machine learning solutions for healthcare. Biopharmaceutical and medical technology companies offering therapies for complex diseases can leverage RightAI to assist with the development of CDSSs based on real-world data and quickly achieve real-world impacts.

“Together with Nordic, BeeKeeperAI’s privacy enhancing platform can address the last mile of AI/machine learning-based CDSS: real-world deployment and ongoing monitoring for performance drift. The ability to develop and deploy solutions in real-world settings enhances and accelerates the impact of CDSS,” said Michael Blum, MD, co-founder and chief executive officer at BeeKeeperAI. “Instead of taking years to achieve impact, RightAI will enable CDSS to impact patient outcomes in a matter of months from the start of development to impact. This acceleration will enable life-changing therapies to reach patients more quickly, fulfilling the promise of healthcare AI.”

Dr. Joseph added, “Following the guiding principles of clinical decision support, RightAI brings the right information to the right provider in the right format through the right channels at the right time to help clinicians improve the precision of their treatment decisions for their patients.”

The partnership continues Nordic and BeeKeeperAI’s leadership in the healthcare AI space. Nordic is a comprehensive delivery partner of BeeKeeperAI’s EscrowAI™, a privacy-enhancing collaboration platform for trustworthy and responsible AI that enables data controllers to maintain control and protect the privacy of their real-world patient data and developers to responsibly develop and deploy AI into the EHR and clinical workflows.

Delray Medical Center First Hospital in Palm Beach County to Successfully Implant New Dissolvable Stent for People with Chronic Limb Threatening Ischemia Below-the-Knee

Delray Medical Center

Delray Medical Center (DMC) successfully implanted the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit™ BTK System), a first-of-its-kind dissolvable stent for people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK).  DMC is the first hospital in Palm Beach County to utilize the Esprit in surgery.

The procedure was completed by vascular surgeon Dr. Joseph Ricotta, National Medical Director of Vascular Surgery and Endovascular Therapy for Tenet Healthcare and Professor of Surgery and Program Director of the vascular surgery fellowship at Florida Atlanta University School of Medicine.

Approved by the U.S. Food and Drug Administration (FDA) in April 2024, the Esprit BTK System is designed to keep arteries open and deliver a drug called everolimus to support vessel healing prior to dissolving.  The Esprit BTK System is comprised of materials similar to dissolving sutures. Once the blockage is open, the device is implanted through a catheter based minimally invasive procedure. The scaffold helps heal the vessel and provides support until it is strong enough to remain open on its own.

“The FDA’s approval of Esprit BTK System is a step forward in below-the-knee therapy. This new treatment option supports healing while reducing the risk of long-term complications,” said Dr. Ricotta.  “We’re excited to be able to offer our patients the latest technological advancements to treat chronic limb-threatening ischemia below-the-knee such as Abbott’s new bioresorbable stent.”

Chronic limb-threatening ischemia below-the knee is a severe form of PAD that occurs when arteries become clogged with plaque, and blood flow and oxygen can’t reach the lower leg and foot. Over 20 million people in the U.S. are living with PAD and only 10% of those people have been diagnosed. PAD disproportionately affects the Black and Hispanic communities with nearly 1 in 3 Black adults and 1 in 5 Hispanic adults developing the disease. Risk factors for PAD also include current or prior smoking, diabetes, high blood pressure, and high cholesterol.

Dr. Ricotta serves as National Medical Director of Vascular Surgery and Endovascular Surgery for Tenet Healthcare and founded and directs the FAU Vascular Surgery Fellowship and is a professor of surgery at FAU School of Medicine. He is a nationally and internationally recognized expert in the field of vascular and endovascular surgery, earned his undergraduate degree at Yale University and his medical degree from Jefferson Medical College. He completed his residency in general surgery at Johns Hopkins Hospital and was a traveling scholar and specialist registrar in vascular surgery at Oxford University in England. In addition, he completed a vascular and endovascular surgery fellowship at the Mayo Clinic in Rochester, Minnesota, followed by an advanced endovascular surgery fellowship at the Cleveland Clinic. He is the first surgeon in the U.S. to use endovascular robotics to perform minimally invasive vascular surgery and has authored more than 300 publications and delivered more than 500 lectures on the national and international stage.  He has been named a Castle Connolly “America’s Top Doctor” 13 years in a row and earned a position on Newsweek’s “America’s Best Vascular Surgeons 2024” list.

For more information about vascular treatments offered at Delray Medical Center, please visit www.delraymedicalctr.com or call (561) 495-0400.

CMR Surgical receives U.S. FDA Marketing Authorization for next-generation Versius Surgical System

CMR Surgical today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the Versius Surgical System (Versius), paving the way for a next-generation versatile, adaptable, and digitally driven surgical robot to be introduced in the United States.

The FDA marketing authorization of Versius is a significant milestone for CMR as Versius is the first multi-port, soft tissue general surgical Robotic Assisted Surgical Device (RASD) to successfully be authorized through FDA’s De Novo application process. Versius is a RASD intended to assist in the precise and accurate control of Versius Surgical endoscopic instruments and is indicated in the U.S. for adult patients 22 years of age and older, eligible for soft tissue minimal access surgery, for cholecystectomy.

Versius is compact and modular, making it a versatile and portable surgical robot that can seamlessly integrate into virtually any operating room to perform cholecystectomy procedures. It can be easily moved between departments, making it suitable for any care setting. Versius is designed to biomimic the human arm, empowering surgeons through optimized port placement together with the dexterity and accuracy of small, fully wristed instruments. Versius offers 3D HD vision, easy-to-adopt instrument control, and a choice of ergonomic working positions, with an open surgeon console that has the potential to reduce stress and fatigue while allowing for clear communication with the surgical team.

Mark Slack, Chief Medical Officer and Co-founder at CMR Surgical, commented: “Securing FDA marketing authorization for Versius for use in cholecystectomy in adult patients is a significant milestone for CMR and, most importantly, for hospitals and patients who will now have greater access to robotic-assisted surgery in cholecystectomy procedures. With FDA authorization, we can now bring our compact and portable surgical robot to the world’s largest healthcare market, expanding the benefits of robotic-assisted surgery with Versius across various care settings in the U.S.”

As a digitally driven system, Versius is rooted in continuous innovation driven through software to ensure customers benefit from the latest technology updates. With a suite of digital apps to support surgeons, surgical teams and hospitals, Versius provides real time insights to improve proficiency and optimize surgical robotic programs. As CMR brings Versius to customers across the U.S., the Company will also roll out its state-of-the art global metrics-based training program. The training pathway draws on cutting-edge technology including Versius Trainer and the Versius eLearning platform, as well as peer to peer education through preceptoring and ongoing guidance and support, ensuring smooth transition from training to the operating room. CMR’s training pathway also includes Versius Virtual Reality and Versius Trainer in VR improving training pathway accessibility.

Massimiliano Colella, Interim Chief Executive Officer at CMR Surgical, commented: “The U.S. is an important strategic market so gaining FDA authorization for Versius for use in cholecystectomy procedures in adult patients is a significant step forward in CMR achieving its mission of bringing minimal access surgery to more patients around the world. The value of Versius as a compact and modular system has been demonstrated by leading hospitals around the world, and we look forward to working closely with hospitals in the U.S. to introduce Versius.”

Erik Wilson, M.D., Division Director and Vice Chair of Surgery at University of Texas McGovern Medical School at Houston, commented: “I have enjoyed being part of the development of Versius since 2017 and it is very exciting that hospitals across the U.S. can benefit from this next-generation technology. The U.S. is a mature market for surgical robots, so it is hard to believe that until today there was little choice when deciding to start a soft tissue robotics program. Versius securing FDA clearance is an important step forward for helping hospitals of any size to be able to offer robotic-assisted surgery.”

The U.S. is an important market with a strong demand for a flexible surgical robotic system that can be used across any care setting. Of nearly 10 million annual major operating room procedures in the U.S., only approximately 2.5% were robotic assisted.i Versius could enable patients to undergo minimal access surgery for cholecystectomy procedures closer to home thanks to this compact, modular, portable system. The FDA authorization of Versius is the first part of a multi-stage strategic plan that will involve initially partnering with a select number of U.S. hospitals, putting CMR and Versius in a strong position to enter the U.S. market and expand its partnership with hospitals across the country.

Steven D. Schwaitzberg, M.D., Chairman of the Department of Surgery at University at Buffalo School of Medicine and Biomedical Sciences, commented: “For more than a decade there has been a rapid expansion of procedures performed with robotic assistance. There has not been enough choice in the surgical arena for robotic systems in the U.S. I am delighted that Versius is entering into the marketplace with FDA marketing authorization. There is a real need for more compact, modular systems that can be adopted for care in a variety of settings. I look forward to exploring these new developments in robotic assisted surgery as Versius comes to the U.S.”

CMR secured CE Mark for Versius in 2019. Globally, Versius is the second most utilized surgical robotic system with over 26,000 surgical procedures completed in seven specialties as approved in those markets.

groninger to Highlight Filling and Closing Unit Series for OTC Pharma and Diagnostics Products At Pack Expo

groninger, a leading manufacturer of filling and closing machines for the global pharmaceutical, consumer healthcare and cosmetics industries, will debut a flexible filling and closing line for medium- to high-volume OTC pharma and diagnostics products requiring hygienic processing at Pack Expo 2024, November 3-6 in Chicago. At Booth W-17023, the company will be highlighting the flexcare 101, developed to meet the heightened sterility requirements of cleanroom class products such as eye drops and nasal sprays.

Capable of processing up to 120 glass or plastic bottles per minute, groninger’s GMP-compliant flexcare 101 ensures hygienic, low-particle conditions throughout the filling and capping process. The machine also stands out for its versatility, and a moving filling needle supports increased output. Other attributes include continuous welds on the sorting bowls for enhanced cleanability, pharma-grade design materials for consistent hygiene, and inspection stations that ensure all packaging components have been properly applied.

The flexcare 101 also is notable for its ergonomics. The module’s hinged outflow openings offer efficient operator access, and integrated IoT features such as energy monitoring, process capability and overall equipment efficiency (OEE) are clearly laid out on an intuitive HMI dashboard.

“Considering their high-value products, our customers are increasingly requesting GMP-compliant machines that are ergonomic, easy to clean and flexible – all without compromising precision and high throughput,” said Otto Helmle, Vice President of Sales for the groninger Consumer Healthcare & Cosmetics division. “The flexcare 101 meets and exceeds these requirements, testament to our decades of experience designing and manufacturing high-performance, pharma-grade processing and packaging equipment.” Other models are available in the flexcare series for higher speeds.

Another series standout that will be on display with live demonstrations at Pack Expo 2024 is the flexcare 10, a small-footprint unit that can fill and close up to 70 non-sterile glass or plastic bottles per minute. Multifunctional for increased versatility and expedited ROI, the module offers a GMP-friendly design and 100% in-process checkweighing, as well as options for gassing either before or after filling, and optional dropper and spray pump insertion capabilities. The flexcare 10 can fill via rotary piston or peristaltic pumps, and handle products with up to two closing components. Standard servo motor-driven pre- and post-torquing ensures precise torque control of caps.

Filling and closing machine for ready-to-use syringes, vials and cartridges
Also at Pack Expo, groninger will highlight its latest machine for filling and closing ready-to-use syringes, vials and cartridges. Suitable for medium-sized batch production, the company’s flexfill provides a standardized, easily qualified and validated manufacturing solution that makes switching between container types and sizes simple and fast. Notably, flexfill does not sacrifice flexibility for speed: the module can handle up to 200 products per minute.

flexfill’s modular concept ensures that 80% of configurations are predefined, enabling expedited deployment and line integration. The machine is essentially a “3-in-1” solution, with groninger’s combifill technology enabling nested syringes, vials and cartridges to be processed on the same platform by changing only container-specific format parts.

groninger’s smartfill technology minimizes product loss, and a no-touch-transfer setup assures aseptic handling of all pre-sterilized primary packaging. All totaled, flexfill’s multifunctionality and speed-to-market makes it a highly attractive processing solution for both pharma companies and contract manufacturing organizations (CMOs).

Bracco Diagnostics and Subtle Medical Announce FDA Clearance of AiMIFY™ Software for Enhanced MRI

Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A, one of the world’s leading companies in the diagnostic imaging business, and Subtle Medical, Inc., a pioneering innovator in artificial intelligence (AI)-powered image acquisition, are thrilled to announce that their collaborative AI-powered software, AiMIFY™, has received FDA clearance as a Class II software as a medical device (SaMD) for magnetic resonance imaging (MRI) of the brain.

This groundbreaking software, exclusively from Bracco Diagnostics and Subtle Medical, is designed to significantly enhance MRI of the brain, particularly for detecting small and poorly enhanced lesions.

“This FDA clearance marks a significant milestone for our innovative product, showcasing its potential to transform MRI,” said Fulvio Renoldi Bracco, Vice Chairman & Chief Executive Officer of Bracco Imaging S.p.A. “By integrating Bracco’s expertise in contrast imaging with Subtle Medical’s cutting-edge deep-learning technology, we are poised to redefine diagnostic precision and efficiency, setting new standards in the field for the ultimate benefit of the patients.”

AiMIFY™ leverages advanced AI technology to amplify the contrast enhancement of brain MR images up to two times the level obtained with a labeled dose of gadolinium-based contrast agents (GBCAs). This enhancement provides radiologists and neuroradiologists with clearer, more detailed images, improving the visibility of small and large lesions compared to standard post-contrast images. The software’s effectiveness has been validated across diverse test data, including various patient demographics, pathologies, lesion sizes, image scanner vendors, MRI sequences, and acquisition orientations.

“We partnered with Bracco to unlock the potential that AI brings to medical imaging,” said Ajit Shankaranarayanan, PhD, Chief Product Officer at Subtle Medical. “The FDA clearance represents a significant milestone for both companies, as we join forces to empower radiological professionals and improve outcomes for patients worldwide with this innovative AI-powered medical imaging solution.”

Bracco and Subtle will participate in the 110th Radiological Society of North America’s (RSNA) Scientific Assembly and Annual Meeting Dec. 1-5, 2024 in Chicago. To learn more, visit the Bracco booth #3300 and the Subtle Medical booth #4739 in the South Hall, Level 3. Additional information about RSNA Technical Exhibits can be found here: https://www.rsna.org/news/2024/october/2024-technical-exhibits-highlights

AiMIFY is manufactured for Bracco Diagnostics Inc. by Subtle Medical Inc. – Menlo Park, CA, USA 94025

AiMIFY is a trademark of Bracco Imaging S.p.A.

Nuclera Closes $75 Million USD Financing

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million). The fundraise was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined by British Patient Capital, the largest domestic investor in UK venture and venture growth opportunities, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings, Michael D. McCreary, Uni Power Group, and Verve Ventures. Taylor Wessing advised Nuclera on the transaction. The investment will enable the continued commercialization of Nuclera’s eProtein Discovery™ benchtop system, particularly in the US and across Europe.

Nuclera’s eProtein Discovery system is designed to speed up protein expression and purification in research labs, including those using AI for protein design. The system reduces the time and cost of these processes by automating construct screening, allowing for protein scale-up, and producing milligram amounts of protein in less than 48 hours, compared to the months or years other methods can take. Using digital microfluidics, protein quality assays, and cell-free protein synthesis on eProtein Discovery cartridges, eProtein Discovery provides rapid access to high-quality proteins at scale, whether using cell-free or cell-based methods.

The eProtein Discovery system has already been installed at contract research organizations (CROs), biotech and biopharma companies, as well as at leading academic institutes, including University College London, University of Cambridge, University of Southampton, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute.

Dr Michael Chen, CEO and co-founder, Nuclera, said: “This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come.”

Dr Michael Wasserman, Chief Operating Officer, Elevage Medical Technologies, commented: “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process. The demand for Nuclera’s technology is expanding rapidly, as AI and structural biology continues to drive the pace of new discoveries in life sciences and drug development. Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe to address their need for bespoke, rapid and convenient delivery of quality proteins.”

Dr Jonathan Milner, Chairman of the Nuclera Board of Directors, founder and former CEO of Abcam, Inc and CEO of Meltwind Advisory, added: “The ability to screen multiple protein expression profiles and print purified proteins in as little as 24 hours will revolutionize laboratory workflows and make a demonstrable impact in research and drug discovery timelines. Aligning with Nuclera more closely following my appointment as Chairman of the Board, I am excited as the Company’s pioneering solution continues to be recognized by the industry and demonstrated through this funding round.”

Top Ingredients to Look for in Beauty Supplements

Beauty Supplements

In the pursuit of radiant skin, luscious hair, and strong nails, more and more people are turning to beauty supplements. These supplements promise to nourish your body from the inside out, promoting healthy hair growth, clearer skin, and strong nails. But with the overwhelming number of beauty supplements available on the market, it can be challenging to know which ones are actually worth your time and money.

What really sets a quality beauty supplement apart is its ingredients. Certain vitamins, minerals, and compounds are known for their benefits in promoting skin health, hair strength, and overall appearance. In this blog post, we’ll take a closer look at the top ingredients to look for in beauty supplements, so you can make informed choices that will bring you closer to your beauty goals.

1. Biotin (Vitamin B7)

Biotin, also known as Vitamin B7, is a well-known and commonly featured ingredient in hair, skin, and nail supplements. It plays a crucial role in the production of keratin, the protein that makes up your hair, skin, and nails. Biotin is often hailed for its ability to strengthen hair, prevent thinning, and improve the health of nails.

While most people get enough biotin through their diets, those who experience brittle nails or hair loss may benefit from adding biotin supplements. Foods like eggs, nuts, and seeds are also excellent sources of biotin. Whether you choose a supplement or focus on biotin-rich foods, this nutrient can give your beauty routine a well-deserved boost.

2. Collagen

Collagen is one of the most sought-after ingredients in beauty supplements, and for good reason. As the most abundant protein in the human body, collagen is responsible for maintaining the structure and elasticity of the skin. However, as we age, collagen production naturally declines, which leads to wrinkles, sagging skin, and decreased skin firmness.

Collagen supplements, typically in the form of hydrolyzed collagen or collagen peptides, help replenish this vital protein. Studies show that collagen supplements can improve skin hydration, elasticity, and reduce the appearance of wrinkles. Collagen is also essential for maintaining the strength of hair and nails, helping to prevent breakage and promote overall vitality.

Incorporating a collagen supplement into your daily routine can help fight the visible signs of aging and keep your skin looking youthful.

3. Hyaluronic Acid

If you’re looking for an ingredient that provides intense hydration, hyaluronic acid should be at the top of your list. While hyaluronic acid is more commonly known for its topical use in skincare products, it is also found in beauty supplements. This powerful humectant has the ability to retain moisture, keeping your skin plump, smooth, and hydrated from within.

By attracting and holding onto water, hyaluronic acid helps to improve skin elasticity and reduce the appearance of fine lines and wrinkles. When used in supplement form, it works internally to support skin hydration, making it an excellent addition to any beauty regimen, especially for those with dry or dehydrated skin.

4. Vitamin C

Vitamin C is a potent antioxidant that plays a key role in skin health, collagen production, and protecting your skin from damage caused by free radicals. It’s one of the best ingredients for brightening your complexion and evening out skin tone. Moreover, vitamin C supports the body’s natural collagen synthesis, enhancing the skin’s ability to stay firm and youthful.

Many beauty supplements feature vitamin C because it helps protect the skin from UV rays and environmental stressors that can cause premature aging. It also aids in wound healing and can reduce the appearance of acne scars. If you’re looking to maintain a glowing, even complexion, adding a vitamin C-rich supplement to your routine can make a big difference.

5. Vitamin E

Vitamin E is another powerful antioxidant that works wonders for both skin and hair. It helps neutralize free radicals and reduce oxidative stress, which can damage skin cells and contribute to aging. Vitamin E also supports the skin’s moisture barrier, preventing dryness and irritation.

In addition to skin benefits, vitamin E promotes scalp health, which in turn supports hair growth and prevents hair breakage. This vitamin is often found in beauty supplements designed to improve skin texture and boost hair shine. It’s a key ingredient for anyone looking to enhance their beauty routine with an antioxidant powerhouse.

6. Omega-3 Fatty Acids

Omega-3 fatty acids, often sourced from fish oil or flaxseed oil, are essential for maintaining the health of your skin, hair, and nails. These healthy fats support skin hydration by strengthening the skin’s lipid barrier, reducing dryness and inflammation. Omega-3s are also known to calm irritated or sensitive skin and help prevent conditions like eczema.

For hair, omega-3s contribute to healthy hair follicles, reduce scalp inflammation, and add shine and smoothness to your locks. Many beauty supplements feature omega-3 fatty acids to promote glowing skin and strong, shiny hair. Since your body cannot produce omega-3s on its own, incorporating a supplement or eating omega-rich foods like salmon and walnuts can provide excellent results.

7. Zinc

Zinc is an essential mineral that plays a crucial role in maintaining healthy skin. It helps regulate oil production, making it particularly beneficial for those with oily or acne-prone skin. Zinc has anti-inflammatory properties that can reduce redness, irritation, and acne flare-ups.

Additionally, zinc supports the production of new skin cells, promotes wound healing, and can even improve skin elasticity. In beauty supplements, zinc is often paired with other key ingredients like biotin and collagen to provide a comprehensive solution for improving skin health and treating conditions like acne.

When it comes to beauty supplements, the right ingredients can make all the difference in achieving your desired results. Biotin, collagen, hyaluronic acid, vitamins C and E, omega-3 fatty acids, and zinc are some of the most effective ingredients to look for when selecting a beauty supplement. Each of these ingredients offers unique benefits that contribute to healthier hair, stronger nails, and more radiant skin.

While supplements can be a valuable addition to your beauty routine, it’s important to remember that they work best when combined with a balanced diet, proper hydration, and a good skincare routine. By incorporating these top ingredients into your supplement routine, you’ll be well on your way to achieving glowing skin, shiny hair, and strong, beautiful nails.

 

Kids Orthodontists in Tampa: Why Early Orthodontic Care Matters

Orthodontists in Tampa

As parents, ensuring your child’s health is a top priority, and dental health is no exception. Many families overlook the importance of early orthodontic care, often waiting until more significant issues arise. In Tampa, parents have access to a variety of professional pediatric orthodontists who specialize in early dental care for children. Early orthodontic treatment can help prevent major dental problems, align teeth properly, and boost children’s self-confidence.

This article aims to guide Tampa parents through the process of finding the best orthodontist for their kids, why early orthodontic intervention is essential, and what you can expect from the orthodontic process. By the end, you’ll have all the tools to ensure your child receives the right dental care at the right time.

What is a Kid’s Orthodontist?

A kids orthodontist, or pediatric orthodontist, specializes in correcting misalignments of the teeth and jaw in children. Unlike general dentists, who focus on overall dental health, orthodontists concentrate on issues such as overcrowded teeth, bite misalignments (overbites, underbites), and jaw irregularities. Pediatric orthodontists are specifically trained to address these concerns in younger patients, making treatment more effective when started at an early age.

According to the American Association of Orthodontists (AAO), it’s recommended that children have their first orthodontic screening by age seven. This early assessment allows orthodontists to identify potential problems before they become more severe, offering early interventions that could save time and money in the long run.

Why Kids Need Orthodontic Care

In Tampa, where kids are active in sports and outdoor activities, dental injuries and issues are quite common. Early orthodontic care is not just about aesthetics but also about preventing long-term health problems. Misaligned teeth can lead to:

  • Difficulty chewing and speaking
  • Increased risk of tooth decay and gum disease
  • Discomfort in the jaw and headaches
  • Problems with tooth wear due to uneven pressure

Tampa’s warm climate and love for outdoor activities might also expose children to more sugary drinks and snacks, increasing the risk of cavities and misalignment due to bad dental habits. By addressing these issues early, Tampa orthodontists can help prevent costly and painful procedures later in life.

Types of Orthodontic Treatments for Kids

There are several types of orthodontic treatments available for children in Tampa, depending on the severity of the dental issue and the child’s age. Here are the most common:

1. Traditional Metal Braces

Metal braces are the most common orthodontic treatment for kids. They consist of metal brackets and wires that gradually move the teeth into the correct position over time. They are durable and effective for more complex cases of misalignment. Many kids even enjoy personalizing their braces with colorful rubber bands.

2. Clear Aligners

Clear aligners, like Invisalign, are a popular alternative for those looking for a less visible treatment option. Although not all kids are eligible for clear aligners, they are a great solution for mild to moderate cases of misalignment. They offer the convenience of being removable, which allows for easier eating and brushing.

3. Retainers

Retainers are typically used after braces are removed to maintain the new position of the teeth. In some cases, a retainer may be used as a preventative treatment to prevent further misalignment before braces are needed.

4. Palatal Expanders

In cases where the jaw is too narrow, a palatal expander may be used to widen the upper jaw and make room for all of the teeth to fit properly. This is often recommended for kids who are still growing, as their jaws can be more easily adjusted.

Each treatment plan is customized to the child’s specific needs, and Tampa orthodontists are skilled at ensuring that kids receive the most appropriate and effective care.

How to Choose the Best Kids Orthodontist in Tampa

Choosing the right orthodontist for your child is crucial for a smooth and effective treatment experience. Here are some factors to consider when searching for the best orthodontist in Tampa:

1. Credentials and Experience

Ensure that the orthodontist you choose is board-certified and specializes in pediatric orthodontics. Experience matters, particularly with younger patients who may need extra care and patience during treatment.

2. Kid-Friendly Environment

Children can often feel anxious about visiting the orthodontist, so it’s important to find a clinic that creates a welcoming and comfortable atmosphere. Look for an office with a friendly staff, engaging decor, and amenities that help ease your child’s nerves.

3. Modern Technology

Orthodontics has evolved significantly in recent years. Seek out a clinic that uses state-of-the-art technology like digital X-rays and 3D imaging, which allows for more accurate diagnosis and treatment.

4. Reviews and Testimonials

Read reviews from other Tampa parents to get an idea of the orthodontist’s reputation. Positive feedback from other families can be a strong indicator of a trustworthy and effective practice.

The Orthodontic Process for Kids: What to Expect

The orthodontic process can be daunting for both children and parents. Understanding what to expect can help alleviate some of that anxiety. Here’s a general overview of the steps involved:

1. Initial Consultation

During the first visit, the orthodontist will assess your child’s dental health by taking X-rays and possibly creating a 3D model of their mouth. This allows the orthodontist to develop a personalized treatment plan.

2. Treatment Plan

After the consultation, the orthodontist will explain the recommended treatment plan, the expected duration, and any costs involved. This is a great time to ask questions and address any concerns you may have.

3. Treatment

Whether your child receives braces, clear aligners, or another treatment, the orthodontist will monitor their progress with regular check-ups every 4 to 8 weeks. Adjustments will be made as necessary to ensure the teeth move correctly.

4. Post-Treatment Care

Once the braces are removed or treatment is completed, your child may need to wear a retainer to maintain the new alignment. Regular visits may still be necessary to ensure the teeth remain in their proper position.

Benefits of Early Orthodontic Intervention

Early orthodontic intervention offers numerous advantages, including:

  • Preventing severe misalignment: Early detection of orthodontic issues can prevent more serious problems from developing.
  • Reducing treatment time: Starting treatment while the child’s jaw is still growing can shorten the overall treatment duration.
  • Boosting self-confidence: A straight smile can significantly improve a child’s confidence and social interactions.

According to a study published in the American Journal of Orthodontics and Dentofacial Orthopedics, children who undergo early orthodontic treatment are less likely to require invasive procedures later on in life.

Conclusion

Early orthodontic care is a vital step in ensuring your child’s overall health and well-being. By seeking out a qualified kids orthodontist in Tampa, you can set your child up for a lifetime of healthy, beautiful smiles. With various treatment options and modern technology, Tampa offers excellent orthodontic care tailored to children’s unique needs. Don’t wait until a problem arises—schedule an orthodontic consultation for your child today and start the journey to optimal dental health.

Frequently Asked Questions (FAQs)

1. At what age should a child first visit an orthodontist?

Answer: The AAO recommends that children visit an orthodontist by age 7. This allows the orthodontist to identify potential issues early on.

2. Are braces painful for kids?

Answer: While the initial adjustment to braces may cause some discomfort, most children adapt quickly, and any pain is usually temporary.

3. Can my child play sports with braces?

Answer: Yes, but it’s important to wear a mouthguard to protect the braces and teeth from injury during contact sports.

4. How long will my child need to wear braces?

Answer: The duration of treatment depends on the severity of the misalignment, but most children wear braces for 18 to 24 months.

5. What is the cost of orthodontic treatment in Tampa?

Answer: The cost varies depending on the treatment type and duration, but the average cost of braces ranges from $3,000 to $7,000.

 

Biocomposites Invests in InfectoTest GmbH | Developers of a Bacterial-specific Point-of-care Test for Periprosthetic Joint infection

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that it has taken a minority-share interest in InfectoTest GmbH (InfectoTest), a biomedical company based in Berlin that is developing innovative point-of-care systems for the diagnosis of infectious diseases.

One of InfectoTest’s lead products in development is InfectoSynovia, a rapid and high-accuracy test that will detect a periprosthetic joint infection (PJI) in less than five minutes.

PJI is a major problem across the world which is growing as the number of joint replacements increases due to ageing populations. In the US alone, the number of hip and knee arthroplasties is expected to quadruple over the next 10 to 20 years. PJI affects more than two per cent of these patients and is now the main reason for revision arthroplasty.

Rapid and accurate diagnosis of PJI is essential to ensuring the patient receives the most appropriate surgical or antimicrobial treatment plan. InfectoSynovia aims to dramatically reduce the diagnosis time to less than five minutes and provide outstanding sensitivity and specificity, using a sample as small as 50 microliters (µl) of synovial fluid.

Thanks to InfectoTest’s unique method of electrochemical analysis, which is aided by software that can help give precise interpretation of results, InfectoSynovia will be capable of detecting low grade and culture-negative infections.

Michael Harris, Chief Executive Officer of Biocomposites, said: “Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximise their chances of full recovery.

“Our investment in InfectoTest GmbH, reaffirms our commitment to providing and investing in a comprehensive range of products for the management of infection in bone and soft tissue.”

Svetlana Karbysheva, MD, PhD., Managing Director of InfectoTest, added: “Our InfectoSynovia test has the potential to revolutionise the diagnosis of periprosthetic joint infection. With the backing of Biocomposites, which has deep expertise in the management of infection in bone and soft tissue, and a significant global distribution network, InfectoTest will now be able to develop this essential test faster and bring it to clinicians and their patients sooner.”

1...789...923Page 8 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330